<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34982644</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7723</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The journal of spinal cord medicine</Title><ISOAbbreviation>J Spinal Cord Med</ISOAbbreviation></Journal><ArticleTitle>Isolated pulmonary recovery in a veteran with late stage bulbar ALS following edaravone treatment and cessation.</ArticleTitle><Pagination><StartPage>638</StartPage><EndPage>642</EndPage><MedlinePgn>638-642</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10790268.2021.1943249</ELocationID><Abstract><AbstractText Label="CONTEXT">Amyotrophic lateral sclerosis (ALS) is a group of rare neurological diseases which cause progressive loss of upper and lower motor neurons at the spinal or bulbar level. ALS affects voluntary muscles of the body which control eating, talking, and moving. Individuals with ALS manifest difficulty breathing on their own due to weakness of the respiratory system. The average life expectancy of individuals with ALS is 2-5 years from the time of diagnosis, with death resulting from respiratory failure. There is no cure for ALS. At present, riluzole and edaravone are the only FDA-approved treatments that impact survival. Adverse reactions to edaravone include hypoxia and respiratory failure. To date, there are no published reports describing isolated dramatic respiratory improvement in ALS with continued global clinical worsening including limb and face function, particularly following edaravone use.</AbstractText><AbstractText Label="FINDINGS">We present a case report of late stage bulbar ALS, in which a dramatic respiratory improvement is seen following edaravone use, and subsequent cessation.</AbstractText><AbstractText Label="CONCLUSION/CLINICAL RELEVANCE">Isolated pulmonary decline and subsequent recovery following cessation of edaravone in the setting of continued systemic neurologic decline has not yet been described and may suggest potential for reversibility of edaravone-related pulmonary decline. Research is needed to evaluate this possibility further, and this case report may lead to further investigation to evaluate this possibility. Alternatively, although less likely, it is possible the observed that pulmonary improvement may either be beneficially attributed to edaravone, or unrelated to edaravone entirely - representing an undescribed phenomenon of isolated pulmonary decline and improvement in the setting of systemic continued ALS progression, possibly related to the bulbar subtype. Further investigation is warranted to evaluate both the role of edaravone in causing in a potentially reversible pulmonary decline upon cessation of the medication, and the possibility of other undefined variables including various subtypes of ALS contributing to this phenomenon.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Susama</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Spinal Cord Injury Service, VAMC, Syracuse, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, SUNY Upstate Medical University, Syracuse, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jungjae</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine &amp; Rehabilitation, SUNY Upstate Medical University, Syracuse, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscemi-Kimmins</LastName><ForeName>Teaghen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brose</LastName><ForeName>Steven W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Spinal Cord Injury Service, VAMC, Syracuse, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine &amp; Rehabilitation, SUNY Upstate Medical University, Syracuse, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Spinal Cord Med</MedlineTA><NlmUniqueID>9504452</NlmUniqueID><ISSNLinking>1079-0268</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="Y">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bulbar onset</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Pulmonary function</Keyword><Keyword MajorTopicYN="N">Vital capacity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34982644</ArticleId><ArticleId IdType="pmc">PMC9246129</ArticleId><ArticleId IdType="doi">10.1080/10790268.2021.1943249</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ravits J, Paul P, Jorg C.. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007;68(19):1571&#x2013;5. doi:10.1212/01.wnl.0000260965.20021.47. Cited in: PubMed; PMID: 17485643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260965.20021.47</ArticleId><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boumediene F, Logroscino G, Couratier P, Babron M.. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46(1):57&#x2013;74. doi:10.1093/ije/dyw061. Cited in PubMed; PMID: 27185810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD.. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010;7(6):557&#x2013;570. doi:10.1016/j.genm.2010.11.010. Cited in PubMed; PMID: 21195356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, et al. . Prevalence of amyotrophic lateral sclerosis - United States, 2012-2013. MMWR Surveill Summ 2016;65(8):1&#x2013;12. doi:10.15585/mmwr.ss6508a1. Cited in: PubMed; PMID: 27490513.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.ss6508a1</ArticleId><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377(9769):942&#x2013;55. doi:10.1016/s0140-6736(10)61156-7. Cited in: PubMed; PMID: 21296405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH.. Amyotrophic lateral sclerosis. Lancet 2017;390(10107):2084&#x2013;98. doi:10.1016/S0140-6736(17)31287-4. Cited in: PubMed; PMID: 28552366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR.. Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med 2017;7(8):1&#x2013;16. doi:10.1101/cshperspect.a024117. Cited in: PubMed; PMID: 28003278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024117</ArticleId><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K.. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci 2010;294(1-2):81&#x2013;5. doi:10.1016/j.jns.2010.03.028. Cited in: PubMed; PMID: 20452624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2010.03.028</ArticleId><ArticleId IdType="pubmed">20452624</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration . FDA approves drug to treat ALS [FDA news release]. Washington (DC): Food and Drug Administration.gov; 2017 May 5. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-als.</Citation></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH.. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447. doi:10.1002/14651858.CD001447.pub3. Cited in: PubMed; PMID: 22419278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y.. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr 2018;62(1):20&#x2013;38. doi:10.3164/jcbn.17-62. Cited in: PubMed; PMID: 29371752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId><ArticleId IdType="pmc">PMC5773834</ArticleId><ArticleId IdType="pubmed">29371752</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore-James M, Salajegheh M, James N.. Retrospective review of respiratory function in the amyotrophic lateral sclerosis (ALS) veteran population with and without edaravone therapy. Neurology 2019;92(15 supplement). S54.009 ISSN 0028-3878. Cited in: Neurology.</Citation></Reference><Reference><Citation>Harrison D, et al. . ALS reversals: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener 2018;19(7-8):495&#x2013;9. doi:10.1080/21678421.2018.1457059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1457059</ArticleId><ArticleId IdType="pubmed">29607695</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Ho HH, Yen DJ, Wang V, Lin KP, Liao KK, Wu ZA.. Reversible motor neuron disease. Eur Neurol 1993;33:387&#x2013;9. doi:10.1159/000116977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000116977</ArticleId><ArticleId IdType="pubmed">8243516</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, et al. . How common are ALS plateaus and reversals? Neurology 2016;86(9):808&#x2013;12. doi:10.1212/WNL.0000000000002251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasoma B, Balfe D, Naik T, Elsayegh A, Lewis M, Mosenifar Z.. Pulmonary function in patients with amyotrophic lateral sclerosis at disease onset. Monaldi Arch Chest Dis 2012;77(3-4):129&#x2013;33. doi:10.4081/monaldi.2012.146.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2012.146</ArticleId><ArticleId IdType="pubmed">23461249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>